Mandatory Convertible Bond 2021/2027

Below you find further information about the issuance of mandatory convertible bonds that was resolved by the Management Board of Epigenomics AG with approval of the Supervisory Board on June 11, 2021.

NOTE:
This website and the information contained therein do not constitute an offer to sell or a solicitation of an offer to buy any securities of Epigenomics AG in the United States of America (“U.S.”) or in any other jurisdiction or to any person if such offer or solicitation is unlawful or not authorized. Users of this website are requested to inform themselves about and to observe any such restrictions. The information set forth on this website must not be distributed in or to the U.S., to “U.S. persons” as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or to publications with a general circulation in the U.S. Each violation of such limitations may constitute a violation of applicable securities laws. The securities of Epigenomics AG (the “Securities”) have not been and will not be registered under the Securities Act and may not be offered or sold in the U.S. unless pursuant to an exemption from registration requirements.

CONVERSION NOTES:

Bondholders shall have the right (the “Conversion Right”) to convert each mandatory convertible bond in its entirety at the conversion price into convertible shares within the first 14 calendar days of each calendar quarter (each, a “conversion period,” as further defined in the terms and conditions of the bonds) beginning on October 1, 2021 (inclusive) and ending on July 15, 2027 (exclusive).

Please note that the conversion price has meanwhile changed according to § 12 (2) of the terms and conditions of the bond.

At the conversion period 1 to 14 October 2021, the conversion price was EUR 1.10.

At the conversion period 1 to 16 January 2023, the conversion price was EUR 4.40.

From the conversion period 1 to 15 January 2024, the conversion price is EUR 22.00.

For further information, please don’t hesitate to contact us:

Epigenomics AG
Bertha-Benz-Straße 5
10557 Berlin

Contact:
Frederic Hilke (IR.on AG)
E-Mail: ir@epigenomics.com
Tel: +49 221 9140-970